|Bid||1.67 x 76300|
|Ask||1.75 x 30000|
|Day's range||1.75 - 1.80|
|52-week range||1.33 - 3.23|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
NDA Filing for Durasert Three-year Treatment for Posterior Segment Uveitis Remains on Track for Late December 2017/ Early January 2018. Conference Call and Webcast Today, November 7th, at 8:30 a.m. ET. ...
WATERTOWN, Mass., Oct. 18, 2017-- pSivida Corp., a leader in the development of sustained release drug delivery products primarily for treating eye diseases, will report results for its first quarter of ...
WATERTOWN, Mass. and SOPHIA ANTIPOLIS, France, Oct. 10, 2017-- pSivida Corp., a leader in the development of sustained release drug products and technologies, and Nicox S.A., the international ophthalmic ...